CORT — Corcept Therapeutics Incorporated

CORT (Corcept Therapeutics) Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Revenue: $164.9 million, up from $157.2 million year-over-year.
• Net Loss: $31.8 million, compared to a net income of $20.5 million in the prior year.
• Cash and Investments: $515 million as of March 31, 2026.
• Revenue Guidance: Increased for 2026 to a range of $950 million to $1.05 billion.

2. Strategic Updates and Business Highlights

• Endocrinology Division: Record new prescriptions and prescribers for medications, with significant growth expected from recent clinical trial results (CATALYST and MOMENTUM) highlighting the prevalence of hypercortisolism in patients with resistant diabetes and hypertension.
• Oncology Division: FDA approval of Lifyorli for platinum-resistant ovarian cancer, with strong early adoption and positive feedback from physicians. The drug is expected to exceed $1 billion in annual revenue by the end of the decade.
• Pipeline Developments: Ongoing studies for relacorilant in Cushing's syndrome and dazucorilant in ALS, with promising early results. Plans to initiate Phase III trials for both drugs later in 2026.

3. Forward Guidance and Outlook

• Cushing's Syndrome Business: Expected to grow to at least $2 billion in annual revenue by the end of the decade, driven by increased awareness and treatment demand.
• Lifyorli: Anticipated to gain significant market share, supported by NCCN guidelines and a favorable safety profile.
• Regulatory Updates: Positive trajectory for relacorilant's NDA and ongoing trials in various solid tumors and conditions.

4. Bad News, Challenges, or Points of Concern

• Net Loss: The shift from net income to a significant net loss raises concerns about profitability in the short term.
• Revenue Impact: Initial revenue dips due to insurance reauthorization processes and the lag in revenue recognition from new patients starting treatment.
• Operational Challenges: Transitioning to a new specialty pharmacy vendor has created a backlog in insurance prior authorizations, which may affect revenue realization.
• Market Competition: Need to differentiate Lifyorli from established competitors like KEYTRUDA, with a focus on specific patient populations.

5. Notable Q&A Insights

• Revenue Guidance Clarification: The increased guidance is primarily driven by the endocrinology business, with oncology contributions expected to grow post-approval of Lifyorli.
• Market Positioning: Lifyorli is positioned as a preferred regimen in a subset of the market, with expectations of strong adoption due to its efficacy and safety profile.
• Pipeline Development: Dazucorilant's Phase III trial will focus on the 300 mg dose, with survival as a primary endpoint. Plans to expand the specialty pharmacy network to manage increasing prescription volumes were discussed, with potential additions expected in Q4 2026.

This summary reflects the key points from the earnings call, highlighting both the positive developments and challenges faced by Corcept Therapeutics in Q1 2026.